Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Key Takeaways For Eli Lilly in the Pharmaceuticals industry, the PE, PB, and PS ratios are all high compared to its peers, indicating overvaluation. The low ROE, EBITDA, and gross profit suggest ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly's (LLY.N), opens new tab high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly shares fell up to 10% after Q3 earnings missed Wall Street expectations, reporting $11.4 billion in revenue and ...

Eli Lilly's blockbuster weight loss drug Zepbound ... of Zepbound and Mounjaro during the period, according to the pharmaceutical giant. But those wholesalers tapped into some of that existing ...

Here is what Baron Funds said about Eli Lilly and Company (NYSE:LLY) in its second-quarter 2024 investor letter. “Shares of global pharmaceutical company Eli Lilly and Company (NYSE:LLY ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...